Dr.. Hubertus ERLEN
New Schering AG CEO named to replace Dr.Vita who retired Dr. Hubertus Erlen has assumed the chairmanship of the executive board of Scher ing AG, suc ceeding Dr. Giuseppe Vita, who retired after 12 years as chairman. Schering AG is a researchbased pharma ceutical company, focused on four business areas: fertility control and hormone therapy, diagnostics and radiopharmaceuticals, der matology as well as therapeutics for disabling diseases. David GOFFREDO Abbott names executive to lead U.S.pharmaceutical business David B. Goffredo has been named senior VP, pharmaceutical operations, Abbott Laboratories. Mr. Goffredo, 48, joined Abbott in 1987. He has held several management positions in Abbott’s domestic pharmaceutical business and, most recently, served as VP, European operations with responsibility for the pharmaceutical, nutritional, and hospital businesses in this region. Mr. Goffredo holds a bachelor’s degree in business administration from Rowan College and a master’s degree in management from Northwestern University’s Kellogg Graduate School of Management. Mr. Goffredo reports to Dr. Jeffrey M. Lei den, executive VP, pharmaceuticals and chief scientific officer. He replaces Arthur J. Hig gins, who has assumed the position of presi dent and CEO of Enzon Inc. John HAMPILOS Kos appoints VP of marketing Kos Pharmaceuticals Inc. appointed John P. Hampilos as VP of mar keting. Mr. Hampilos is responsible for the mar keting, promotion, and physician education efforts for all of the company’s products, including the company’s new extendedrelease niacin/lovas tatin combination product, Advicor, which is directed since announcing his retirement plans in 1998. Mr. Heimbold will remain chairman until his retirement. Mr. Dolan, 45, becomes the seventh CEO in the corporation’s 114year history. A 13 year veteran of the company, he retains his title of president and remains a member of the board. Mr. Dolan was named CEOdesignate in February. “Peter Dolan exhibits the exemplary lead ership skills required to both capitalize on the tremendous opportunities before us and to meet the challenges ahead, including the growing public expectations for better and more widely accessible medicines,” Mr. Heim bold says. “Under Peter’s stewardship, Bristol Myers Squibb will continue to enhance its rep utation for superior talent, quality products, and scientific excellence. And the company will continue to uphold its commitment to serving the healthcare needs of the public and to delivering value to its shareholders.” As the new CEO, Mr. Dolan will concen trate on implementing the company’s plan to double sales, earnings, and earningspershare by 2005 through a greater focus on its medicines business, external development, and an accelerated pipeline of new products, among other measures. “I look forward to building on Charlie Heimbold’s record of leadership and accom plishment,” Mr. Dolan says. “I will be work ing with my thousands of colleagues around the world to accelerate our growth and to make a difference in the lives of people every where.” Mr. Dolan most recently was responsible for the company’s worldwide medicines, beau ty care, and nutritional businesses. He has also served as senior VP for corporate strategic planning and as president of four different business units: the European Medicines busi ness, the Medical Devices and Nutritional Group, Mead Johnson Nutritionals and Bris tolMyers Products. He joined the company in 1988 as VP of marketing for BristolMyers Products. David BRENNAN AstraZeneca appoints new executive VP for North America In July, David R. Bren nan became executive VP for North America, and president and CEO of AstraZeneca LP in the United States. Tony Zook succeeds Mr. Brennan as senior VP, commercial operations for the U.S. business. These appointments follow the retirement of CG Johansson, executive VP, after 37 years of service with the company. Mr. Brennan started his career at Merck & Co. Inc. in 1975 as a sales representative. He held sales and marketing positions of increas ing responsibility in the United States and international divisions before joining AstraMerck in 1992. There he was responsible for the marketing and sales planning areas, the gastrointestinal and cardiovascular business units, and later led the operating committee. Mr. Brennan, 47, held similar roles at Astra Pharmaceuticals in 1998, and then went on to lead the commercial area for AstraZeneca LP. For the last two years he was senior VP. Peter DOLAN BristolMyers Squibb’s CEO steps down; replacement named As part of its planned leadership transition to support company growth strategy, Bristol Myers Squibb Co. announced that Peter R. Dolan has succeeded Charles A. Heimbold, Jr., as CEO of the $18 billion diversified glob al health and personalcare company. This marks another step in the smooth and orderly transition of leadership that Mr. Heimbold has Pharma POOL TALENT pool 58 J u l y / A ug u s t 20 01 PharmaVOICE under review by the FDA for the treatment of dyslipidemia, or multiple lipid disorders. Upon approval, Advicor will be jointly launched and marketed by Kos and its copro motion partner, DuPont Pharmaceuticals Co. Mr. Hampilos, 41, joins Kos, a specialty pharmaceutical company, following a 13year career at BristolMyers Squibb Co., where he served in a variety of sales and marketing management positions with specific experi ence in launching products in the cholesterol area. Mick MOSEBROOK Pfizer names replacement for industry veteran Hank McCrorie Executive VP Hank McCrorie stepped down as head of sales for U.S. Pharmaceuticals effective July 1, after 40 years of service at Pfizer. Mr. McCrorie is being replaced by Mick Mosebrook, senior VP, sales, who reports directly to Karen Katen, executive VP of Pfiz er and president of Pfizer Pharmaceuticals Group. “Mick is the right choice to continue our focus on performance, teamwork, and people development,” Ms Katen says. Mr. Mosebrook, a graduate of Texas Chris tian University, joined Pfizer Labs in 1968, after serving four years as an officer in the U.S. Air Force. He held increasingly responsible positions in Pfizer Labs, becoming VP Sales, in 1991. He was appointed group VP, sales U.S. Pharmaceuticals in 1998. Joe SCHACHLE Inspire Pharmaceuticals appoints newVP,marketing and sales Inspire Pharmaceuti cals Inc. has appointed Joe Schachle as VP, marketing and sales. Mr. Schachle is responsible for strategic product planning as well as the development of a marketing and sales infrastructure in North America to handle Inspire’s future commercial efforts. Mr. Schachle, with more than 12 years experience in the pharmaceutical industry and more than a half dozen product launches, has the expertise required to bring Inspire’s prod ucts to market. Mr. Schachle most recently served as direc tor of marketing at GlaxoSmithKline in the respiratory area, with overall responsibility for the U.S. launch of Advair for asthma. In his nineyear tenure at GlaxoSmithKline, Mr. Schachle held various positions in sales, mar keting, and new product planning. Richard VANDUYNE New senior VP and head of business development at Pharmacia Pharmacia Corp. has appointed Richard Van Duyne senior VP, business development. Mr. Van Duyne is responsible for a full range of business development activities, including acquisitions, equity investments, joint ven tures, and strategic alliances. Mr. Van Duyne joins Pharmacia from MedPointe Capital Partners LLC, a private equity investment company, where he served as managing director. He was previously VP of corporate development and licensing at Warn erLambert Co. where he spent 16 years in a variety of key roles. Mr. Van Duyne replaces Mats Pettersson, who has been named CEO of Pharmacia’s biotech spinoff, Biovitrum, in Sweden. Biotech POOL David EBERSMAN Genentech appoints senior VP, product operations Genentech Inc. has promoted David Ebers man to senior VP, product operations, with responsibility for global manufacturing, facili ties, engineering, and supplychain manage ment. Mr. Ebersman reports to Susan D. Hell mann, M.D., executive VP, development and product operations, and chief medical officer. Mr. Ebersman, 31, who has been with Genentech since 1994, held several positions in business and product development. He was named senior director of product development in 1998 and VP in 1999. Before joining Genentech, Mr. Ebersman was a research ana lyst at Oppenheimer & Co. Inc., an invest ment banking company. Michael SABOLINSKI Organogenesis appoints new president and CEO Organogenesis Inc. has appointed Michael L. Sabolinski, M.D., to the positions of presi dent and CEO. He replaces Philip M. Laugh lin, who has resigned from these positions. Previously, Dr. Sabolinski was senior VP of medical and regulatory affairs at the company. Since joining Organogenesis in 1992, Dr. Sabolinski has held several positions, includ ing responsibilities for clinical research, corpo rate development, medical, and regulatory affairs. He led the company’s successful devel opment of its leading woundcare product, Apligraf, from initiation of clinical trials to commercialization. “Mike brings extensive experience in the fields of wound healing and tissue engineer ing, with a broad understanding of the tech nologies and the markets,” Mr. Laughlin says. Supplier POOL Carl SPALDING Parexel announces executive promotions Parexel International Corp., a contract pharmaceutical outsourcing organization, has appointed Carl A. Spalding as president and chief operating officer. Josef H. von Ricken bach, who had also been serving in this capac ity, will continue to serve as Parexel’s CEO and chairman. In his new position, Mr. Spalding assumes responsibility for the operations of the clinical research services, the Parexel consulting group, and the medical marketing service’s strategic business units, as well as for the administrative management of the company. Mr. von Rickenbach continues to oversee the perceptive informatics business. Mr. Spalding brings more than 30 years of extensive healthcare management experience. He served most recently as an executive VP and group president at Cardinal Health Inc., with responsibility for several businesses pro viding services to the bio/pharmaceutical industry. Before Cardinal Health, Mr. Spalding served for six years as VP and general manag er of pediatric products for the Ross Products Division of Abbott Laboratories. Previously, Mr. Spalding was with Johnson & Johnson for more than 22 years in a variety of domestic and international management positions. “Carl’s experience in and knowledge of the bio/pharmaceutical industry will be instru mental to the further success of the company’s core businesses,” says Mr. von Rickenbach.

Download PDF